CG Oncology (NASDAQ:CGON) Stock: Insider Arthur Kuan Acquires 30,000 Shares

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) CEO Arthur Kuan bought 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The stock was purchased at an average cost of $78.88 per share, with a total value of $2,366,400.00. Following the purchase, the chief executive officer directly owned 228,916 shares in the company, valued at $18,056,894.08. The trade was a 15.08% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CG Oncology Trading Up 2.4%

NASDAQ:CGON opened at $81.90 on Friday. The firm has a market cap of $7.32 billion, a price-to-earnings ratio of -29.67 and a beta of 0.35. The company’s 50-day moving average is $68.71 and its two-hundred day moving average is $67.10. CG Oncology, Inc. has a 12-month low of $37.01 and a 12-month high of $93.95.

CG Oncology (NASDAQ:CGON – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. On average, equities research analysts forecast that CG Oncology, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on CGON shares. HC Wainwright lifted their target price on CG Oncology from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler boosted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Truist Financial reiterated a “buy” rating and set a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research report on Tuesday. Morgan Stanley increased their price objective on shares of CG Oncology from $102.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Wall Street Zen raised shares of CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $102.22.

Read Our Latest Research Report on CGON

Institutional Trading of CG Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ghisallo Capital Management LLC bought a new position in CG Oncology in the 3rd quarter valued at approximately $5,317,000. Virtu Financial LLC acquired a new stake in CG Oncology during the 3rd quarter worth approximately $295,000. Aquatic Capital Management LLC boosted its position in CG Oncology by 111.2% during the 3rd quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company’s stock worth $1,732,000 after buying an additional 12,867 shares during the period. Goldman Sachs Group Inc. grew its holdings in CG Oncology by 32.5% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after acquiring an additional 278,751 shares during the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of CG Oncology by 177.7% during the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock valued at $56,618,000 after acquiring an additional 511,044 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors.

Key Headlines Impacting CG Oncology

Investors following CGON have been watching these headlines:

  • Positive Sentiment: CEO Arthur Kuan bought 30,000 shares for about $2.37 million, while insider Isabel Kalofonos purchased 3,751 shares for roughly $299,000. The buying—about $2.7 million combined—may signal confidence, particularly as the CEO described the trial results as a “defining milestone.” Insider purchases and trial results
  • Positive Sentiment: HC Wainwright kept its Buy rating and $115 target while raising its EPS forecasts for FY2028, FY2029 and FY2030. The higher estimates suggest the analyst sees improving longer-term earnings potential. HC Wainwright analyst outlook
  • Negative Sentiment: Director Leonard Post sold 1,000 shares, halving his direct stake. The sale was relatively small compared with the company’s overall value, and was outweighed in scale by the reported insider purchases. Director’s SEC filing

About CG Oncology

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Featured Stories

Insider Buying and Selling by Quarter for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.